The India BioEconomy Report (IBER) 2026:
Union Minister unveiled the India BioEconomy Report (IBER) 2026 during the 14th Foundation Day of BIRAC in New Delhi.
- The report highlights that India’s bioeconomy reached a record $195.3 billion in 2025, now contributing nearly 5% to the national GDP.
- The IBER 2026 is a comprehensive annual document developed by the Association of Biotechnology Led Enterprises (ABLE).
- It serves as the primary benchmark for measuring the growth, sectoral contributions, and startup ecosystem of India’s biotechnology sector, tracking the country’s progress toward its long-term economic goals.
Key Summary Points of the Report:
- Record Market Size: India’s BioEconomy grew by $29.6 billion in 2025 to reach a total of $195.3 billion.
- Highest Growth Rate: The sector witnessed an 18% growth in 2025, the highest rate recorded in recent years.
- GDP Contribution: The BioEconomy’s share of the national GDP rose to 4.8%, up from 4.2–4.3% in previous years.
- Sectoral Leader: The BioIndustrial segment was the largest contributor, valued at $90.2 billion.
- BioPharma Strength: This segment reached $64.5 billion, with significant growth expected in biosimilars and peptide manufacturing as global patents expire.
- BioServices and Agri: BioServices contributed $26 billion, while BioAgri accounted for $14.6 billion of the total economy.
- GCC Expansion: India now hosts over 150 healthcare and life sciences Global Capability Centres (GCCs), employing 300,000+ professionals.
- Startup Surge: The number of registered biotech startups rose to 11,855, with 1,780 new startups established in 2025 alone.
